Apolipoprotein B modifies the association between lipoprotein(a) and atherosclerotic cardiovascular disease (ASCVD) risk
Authors' conclusion
In the context of primary prevention, ASCVD risk associated with Lp(a) was observed only when apoB was elevated.
Study context
- Population
- Community-based population without baseline CVD (Atherosclerosis Risk in Communities (ARIC) study)
- Participants
- 12,988 participants
- Exposure
- Elevated vs non-elevated Lp, by apolipoprotein B (apoB) level
- Outcome
- ASCVD
Methodological detailssecondary analysis of the ARIC study, community-based
- Secondary analysis of the ARIC study
- Community-based
Main finding
As reported in the abstract
Hazard ratio (95% CI)P value
High Lp(a), apoB ≥89 mg/dlvs Concordantly low Lp(a)high Lp(a) raised risk only when apoB elevated
1.48(1.34–1.63)
P < 0.001Elevated apoB (≥89 mg/dl)independent association
1.19(1.08–1.30)
P < 0.001Elevated Lp(a) (quintile 5)independent association
1.27(1.16–1.40)
P < 0.001- ASCVD events
- 3,888
- Coronary heart disease (CHD) events
- 1754
Observational data: associations, not effects.
Original publication
Apolipoprotein B modifies the association between lipoprotein(a) and ASCVD risk. Am Heart J. Published 5 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →